DUBLIN--(BUSINESS WIRE)--The "Thoracic Aortic Stent Grafts-Pipeline Insight and Competitive Landscape, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Thoracic Aortic Stent Grafts-Pipeline Insight and 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Thoracic Aortic Stent Grafts pipeline landscape.
These are essentially used for endovascular repair of abdominal and thoracic aortic aneurysms. Increasing geriatric population, poor dietary habits, and high incidence of Cardiovascular Diseases (CVDs) are some of the factors impelling the demand for novel treatments and devices for thoracic and abdominal aneurysm repair, which, in turn, is expected to drive the market.
Smoking, which has become a global concern, is also contributing to the growth of this market. This report provides a detailed study of the emerging Thoracic Aortic Stent Grafts devices along with competitive landscape to help better understand the emerging Thoracic Aortic Stent Grafts devices.
Thoracic Aortic Stent Grafts Devices Competitive Assessment
This segment of the Thoracic Aortic Stent Grafts report encloses its detailed analysis of various pipeline devices which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates and the latest news and press releases. The report also provides list of major players involved in the pipeline product development.
Treatment Type
Thoracic Aortic Stent Grafts can be divided based on Treatment Types - Open Surgical Repair (OSR), Endovascular Aneurysm Repair (EVAR), Abdominal Aortic Aneurysm Repair, Thoracic Aortic Aneurysm Repair & Thoracic Endovascular Aneurysm Repair.
Major Players in Thoracic Aortic Stent Grafts
There are approx. 20+ key companies which are developing the products for Thoracic Aortic Stent Grafts.
Nellix System: Endologix
Nellix is being evaluated for its safety and effectiveness. Nellix EndoVascular Sealing System will be implanted into eligible patients. Enrolled patients will undergo a high resolution, contrast-enhanced computed tomography angiography (CT) scan of the relevant aortic and aortoiliac vasculature within three months of the scheduled procedure and at specified follow-up intervals post-implantation. The Primary study completion date is March 2025.
NEXUS: Endospan Ltd.
NEXUS is being developed by Endospan Ltd. The purpose of the study is to evaluate the safety and performance of the Nexus Aortic Arch Stent Graft System for the endovascular treatment of thoracic aortic pathologies requiring landing in the Aortic Arch. The Nexus Aortic Arch Stent Graft System is indicated for the endovascular treatment of thoracic aortic pathologies involving the aortic arch (such as aneurisms and dissections).
The device is intended to exclude the lesion from the blood circulation in patients diagnosed with thoracic aortic pathology and who have appropriate anatomy to accommodate the Nexus system in an endovascular procedure. The primary objectives of the study are to evaluate the safety and performance of the Nexus Aortic Arch Aneurysm Stent Graft System. The device is currently available for sale in Europe and is intended for investigational use only in the U.S. The primary study completion date is expected to be October 2023.
Thoracic Aortic Stent Grafts Competitive Benchmarking
This segment of the reports provides analysis of the pipeline report to give a clear understanding of the comparative analysis.
The analysis is based on
- Brand Positioning of Leading companies
- Application
- Industry Collaborations
Thoracic Aortic Stent Grafts: Commercialization Activity
This segment of the report provides a detailed list of any commercial activity in the field of THORACIC AORTIC STENT GRAFTS devices ranging from collaboration, mergers and acquisition, recent breakthrough among others.
Development Activities
- In October 2020 Cook Medical announced that the Zilver Vena received FDA premarket approval (PMA) in the United States. The product is expected to be commercially available to physicians in the U.S. in Q4 2020. Zilver Vena is a self-expanding stent approved to treat patients suffering from iliofemoral venous disease. Venous disease is a condition where the body cannot properly pump blood through veins back to the heart.
- In July 2020, Medtronic plc, the global leader in medical technology, announced the start of a prospective, observational, global, multi-center, real-world, post-market study to evaluate the safety and effectiveness of the Valiant Navion Thoracic Stent Graft System in the treatment of thoracic aortic dissection. The first patient procedure in the DISSECT-N study was performed at Northwell Health in New York, New York by Derek Brinster, M.D., director of Aortic Surgery.
Key Players
- Cook Medical, Inc
- W.L. Gore & Associates
- Medtronic Plc
- Lombard Medical, Inc
- Endologix, INC
- Terumo Corporation Inc.
- Cardinal Health Inc
- Becton
- Dickinson and Company
- Cryolife Inc.
- MicroPort Scientific Corporation
- Evasc Medical Systems Corp.
- St. Jude Medical, Inc.
- TriVascular and Inc.
Key Topics Covered:
1. Key Insights
2. Thoracic Aortic Stent Grafts: Snapshot
3. Thoracic Aortic Stent Grafts
4. Thoracic Aortic Stent Grafts: Competitive Assessment
5. Thoracic Aortic Stent Grafts: Competitive Benchmarking: By Company
6. Thoracic Aortic Stent Grafts: Commercialization Activity
7. Thoracic Aortic Stent Grafts: Regulatory
8. Thoracic Aortic Stent Grafts: Reimbursement
9. Thoracic Aortic Stent Grafts: Market Dynamics
10. Analytical Perspective
11. Conclusion
12. Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ejokqr
